Startup Israel: ‘Promise Bio’ Emerges starts with $8.3M Seed

 Promise Bio, a startup based in Tel Aviv, wants to transform immune-mediated disease treatment with advanced precision medicine solutions. Today the company announced its emergence from stealth with an $8.3 million seed investment.

This funding will accelerate the development of Promise Bio’s computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development.

The Challenge

“Current biological treatments for autoimmune diseases don’t work in all patients, with only 30-40% of patients achieving significant remission. At Promise Bio, our mission is to eliminate the trial-and-error approach by introducing tools for data-driven decisions,” said Ronel Veksler, Co-founder & CEO of Promise Bio. 

The Solution

The key to addressing this challenge lies in focusing on the right biological data—proteins, the building blocks of our body. It’s not just about protein levels but understanding the changes they undergo after formation. The PROMISE (Protein Modification Integrated Search Engine) platform does exactly that, enabling us to get closer to bringing precision medicine to diseases that currently lack effective tools.

The Way

Promise Bio’s innovative platform is rooted in years of foundational research conducted by Dr Assaf Kacen, Co-Founder & CTO of Promise Bio, in the lab of Prof. Yifat Merbl, Scientific Co-Founder of the company, at the Weizmann Institute of Science.

The groundbreaking research into protein modifications and immune response, featured in Nature Biotechnology in 2023, laid the foundation for developing Promise Bio’s computational platform.

Kacen built on this research to create a system that enables broad-scale profiling of dozens of post-translational modifications (PTMs) from mass-spectrometry data without needing customized chemical enrichment or additional lab procedures.

based on the company press release. Selected as relevant/regrouped/edited by VonNaftali. Pic AI-generated. Emblematic